Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR

Triple-negative breast cancer (TNBC) does not express conventional therapeutic targets and is the only type of malignant breast cancer for which no designated FDA-approved targeted therapy is available. Although overexpression of epidermal growth factor receptor (EGFR) is frequently found in TNBC, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan-Liang, Overstreet, Anne-Marie, Chen, Min-Shan, Wang, Jiang, Zhao, Hua-Jun, Ho, Po-Chun, Smith, Molly, Wang, Shao-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484446/
https://www.ncbi.nlm.nih.gov/pubmed/25883211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484446/
https://www.ncbi.nlm.nih.gov/pubmed/25883211

Ejemplares similares